Cargando…

Clinical trial simulations in pulmonary fibrosis: patient-focused insights and adaptations

BACKGROUND: Patient recruitment and retention are a challenge when conducting clinical trials in patients with pulmonary fibrosis, including idiopathic pulmonary fibrosis and other interstitial lung diseases. This study aimed to understand and address the barriers associated with trial participation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, Steve, Flewett, Maxine, Flewett, Ron, Lee, Sharon, Vick, Bill, Thompson, Milla, Pinnetti, Sabine, Zoz, Donald F., Hoffmann-Vold, Anna-Maria, Kreuter, Michael, Maher, Toby M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2023
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227627/ https://www.ncbi.nlm.nih.gov/pubmed/37260456 http://dx.doi.org/10.1183/23120541.00602-2022

Ejemplares similares

Lung transplantation: the patient view from either side of the operating table
por: Williams, Clare, et al.
Publicado: (2021)

The rotaviruses
por: Flewett, T. H., et al.
Publicado: (1978)

Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis
por: Maher, Toby M., et al.
Publicado: (2022)

Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey
por: Moor, Catharina C., et al.
Publicado: (2019)

Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Call to Arms
por: Kreuter, Michael, et al.
Publicado: (2020)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
por: Richeldi, Luca, et al.
Publicado: (2023)

AN ENVELOPED VIRUS IN STOOLS OF CHILDREN AND ADULTS WITH GASTROENTERITIS THAT RESEMBLES THE BREDA VIRUS OF CALVES
por: Beards, G.M., et al.
Publicado: (1984)

Eye movement desensitization and reprocessing (EMDR) therapy for posttraumatic stress disorder in adults with serious mental illness within forensic and rehabilitation services: a study protocol for a randomized controlled trial
por: Every-Palmer, Susanna, et al.
Publicado: (2019)

Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2022)

The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2020)

ROTAVIRUS ENTERITIS IN THE WEST MIDLANDS DURING 1974
por: Bryden, A.S., et al.
Publicado: (1975)

Soft X-ray magnetic scattering studies of 3D magnetic morphology along buried interfaces in NiFe/CoPd/NiFe nanostructures
por: Flewett, Samuel, et al.
Publicado: (2019)

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
por: Kreuter, Michael, et al.
Publicado: (2015)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
por: Maher, Toby M, et al.
Publicado: (2023)

Global incidence and prevalence of idiopathic pulmonary fibrosis
por: Maher, Toby M., et al.
Publicado: (2021)

Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease
por: Kreuter, Michael, et al.
Publicado: (2022)

Fatum Inexorabile: Do Monocytes Predict the Fate of Interstitial Lung Abnormalities?
por: Kreuter, Michael, et al.
Publicado: (2022)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

Probing of three-dimensional spin textures in multilayers by field dependent X-ray resonant magnetic scattering
por: Burgos-Parra, Erick, et al.
Publicado: (2023)

Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial
por: Kreuter, Michael, et al.
Publicado: (2023)

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
por: Kreuter, Michael, et al.
Publicado: (2021)

Small Airways in Idiopathic Pulmonary Fibrosis: Quiet but Not Forgotten
por: Maher, Toby M.
Publicado: (2021)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE
por: Nakshbandi, Gizal, et al.
Publicado: (2023)

The treatment of idiopathic pulmonary fibrosis
por: Woodcock, Hannah V., et al.
Publicado: (2014)

Recent advances in understanding idiopathic pulmonary fibrosis
por: Daccord, Cécile, et al.
Publicado: (2016)

Targeting Human Herpesviruses: An Effective Strategy for Treating Idiopathic Pulmonary Fibrosis?
por: Maher, Toby M.
Publicado: (2021)

Biomarkers for Interstitial Lung Abnormalities: A Stepping-stone Toward Idiopathic Pulmonary Fibrosis Prevention?
por: Maher, Toby M.
Publicado: (2022)

Current and novel drug therapies for idiopathic pulmonary fibrosis
por: Adamali, Huzaifa I, et al.
Publicado: (2012)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)

Therapie von Lungenfibrosen bei rheumatischen Systemerkrankungen (neue Therapien)
por: Buschulte, Katharina, et al.
Publicado: (2021)

Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent, et al.
Publicado: (2015)

Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK
por: Strongman, Helen, et al.
Publicado: (2018)

Cellulite: a review with a focus on subcision
por: Friedmann, Daniel P, et al.
Publicado: (2017)

Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
por: Kolb, Martin, et al.
Publicado: (2023)

Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States
por: Fan, Yanni, et al.
Publicado: (2020)

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
por: Woodcock, Hannah V, et al.
Publicado: (2013)

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
por: Santermans, Eva, et al.
Publicado: (2019)

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)
por: Maher, Toby M, et al.
Publicado: (2019)

Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i7olspce9mnatu071mffugjuov